Applications are open
Apply Today
US flu vaccines are likely to move from quadrivalent to trivalent due to a change in circulating influenza viruses, says University of Michigan School of Public Health researcher Arnold Monto.
The Food and Drug Administration’s expert vaccine advisory panel on Thursday unanimously endorsed the idea of taking a strain of influenza viruses that no longer appears to circulate out of flu shots as quickly as possible, pressing the FDA and manufacturers to try to get the work done on an expedited timeline.
The University of Michigan School of Public Health is among 13 institutions that will receive funding from the Centers for Disease Control and Prevention as part of a network of centers focused on predicting and preparing for future disease outbreaks.
According to a new study published in the journal Clinical Infectious Diseases, while there have been major advances over the last decade in an effort to improve the effectiveness of seasonal influenza vaccine, innovative approaches are needed to significantly improve vaccine effectiveness. Study author Arnold Monto, professor of Epidemiology at the University of Michigan School of Public Health, discusses the findings.
For outstanding contributions to respiratory virus disease research over the course of his career, Dr. Arnold Monto, the Thomas Francis, Jr. Collegiate Professor of Public Health, has received the Lifetime Achievement Award from the International Society for Influenza and other Respiratory Virus Diseases (ISIRV).
A recurring sentiment among some in the vaccine-hesitant community is a desire to wait to receive any of the three available COVID-19 vaccines until they have been officially approved by the Food and Drug Administration. And while the FDA has authorized the Pfizer, Moderna and Johnson & Johnson vaccines―and is expected to also approve each one in turn―for many people, the difference between “authorized” and “approved” has been confusing.